Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
At a maximum tolerated dose of nivolumab (Opdivo) 3 mg/kg or 1 mg/kg+ipilimumab (Yervoy) 3 mg/kg, 42% of patients in the combined group achieved best intracranial response vs 20% in the single groups of this phase 2 trial.
Why this matters
Previous trials excluded patients with untreated brain metastases but found compounds active.
This examines the antitumour activity and safety in patients with no prior therapy.
Phase 2, open-label trial (n=76) of patients naive to anti-PD1/PDL1/PDL2/CTLA4.
Patients randomly assigned to:
—A: nivolumab 1 mg/kg+ipilimumab 3 mg/kg, every 3 wk×4 cycles, and then nivolumab 3 mg/kg every 2 wk.
—B: nivolumab 3 mg/kg every 2 wk.
—C: nivolumab 3 mg/kg every 2 wk had brain metastases that failed therapy, were symptomatic, or pat...